Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 514

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 2
Chunk 514
---
,557  $10,980  $(8,423 )Current Liabilities  1,772   1,291   481 Working Capital $785  $9,689  $(8,904 )

Our total current assets as of December 31, 2024, were $2.6 million as compared to total current assets of $11.0 million as of December 31, 2023. The decrease in current assets was primarily due to the funding of our operating activities.

Our total current liabilities as of December 31, 2024, were $1.8 million as compared to total current liabilities of $1.3 million as of December 31, 2023.

Historical Cash Flows

The following table summarizes our cash flows for the periods indicated:

  Year ended     December 31,   (In thousands) 2024  2023  Change Cash flows used in operating activities $(8,350 ) $(8,207 ) $(143 )Cash flows provided by investing activities  7,769   3,507   4,262 Cash flows provided by financing activities  112   567   (455 )Effect of exchange rate changes on cash  (8 )  60   (68 )Net change in cash and cash equivalent during period $(477 ) $(4,073 ) $3,596 

 57Table of contents

Cash Flows from Operating Activities

During the year ended December 31, 2024, cash used in operating activities was $8.4 million compared to $8.2 million during the year ended December 31, 2023. Cash used in operating activities during the year ended December 31, 2024, was attributed to a net loss of $9.8 million and a non-cash gain of $0.3 million associated with our trading of marketable securities offset by decreases in operating assets and liabilities of $0.9 million and non-cash stock-based compensation of $0.8 million. Cash used in operating activities during the year ended December 31, 2023, was attributed to a net loss of $9.3 million and a non-cash gain of $0.6 million associated with the Company’s trading of marketable securities offset by increases in operating assets and liabilities of $0.7 million and non-cash stock-based compensation of $1.0 million